Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results
February 10, 2022 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday,...
Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation
December 28, 2021 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Ranks as a Top Place to Work for 2021 by The Boston Globe
December 06, 2021 09:29 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Announces $25 Million Accelerated Share Repurchase Program
November 15, 2021 08:30 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
UPDATE: Collegium to Participate in Upcoming Conferences
November 11, 2021 16:54 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium to Participate in Upcoming Conferences
November 11, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Reports Third Quarter Fiscal 2021 Results
November 04, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
- Board of Directors Has Authorized $25 Million Accelerated Share Repurchase Program -- Net Income of $8.0 Million and Adjusted EBITDA of $37.3 Million -- Full-Year 2021 Guidance Updated -- Conference...
Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
October 21, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference
September 13, 2021 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium to Participate in Upcoming Investor Conferences
September 01, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...